- Published at
- by manilatimes.net
mixed
mixed
News for Eidos Therapeutics Inc (EIDX)
- Published at
- by seekingalpha.com
positivepositiveBridgeBio Pharma: Assessing Acoramidis' Market Opportunity (NASDAQ:BBIO)
BridgeBio's acoramidis seems likely to secure approval in November, in the large market of ATTR-cardiomyopathy. Read more to see our analysis on BBIO stock.- Published at
- by marketscreener.com
mixedmixedBridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial
- Phase 3 open-label, single-arm study conducted in Japan by BridgeBio licensing partner Alexion, AstraZeneca Rare Disease showed consistency with global ATTRibute-CM Phase III trial - No mortality...- Published at
- by markets.businessinsider.com
mixedmixedAeglea BioTherapeutics Changes Name To Spyre Therapeutics; To Begin Trading Under Symbol SYRE
(RTTNews) - Aeglea BioTherapeutics, Inc. (AGLE) announced its name change to Spyre Therapeutics, Inc. Effective as of market open on November 28, ...- Published at
- by globenewswire.com
positivepositiveAL Amyloidosis Therapeutics Market is projected to rise at a 7.3% CAGR until 2033, being valued at US$ 4.56 billion | Future Market Insights, Inc.
Reaching US$ 4.56 Billion by 2033, AL Amyloidosis Therapeutics to be most Useful for Chemotherapy, commanding over 50% of all Applications. North American...- Published at
- by thestreet.com
mixedmixed- Published at
- by globenewswire.com
positivepositiveBridgeBio Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Business Update
–Secured up to $750 million in non-dilutive debt financing in November 2021, extending BridgeBio’s financial runway into 2024 –Dosed first patient in...- Published at
- by prnewswire.com
mixedmixedBridgeBio Pharma, Inc. Reports Second Quarter 2021 Financial Results and Business Update
/PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company founded to discover, create,...- Published at
- by gurufocus.com
mixedmixed- Published at
- by globenewswire.com
mixedmixedBright Peak Therapeutics gibt Serie-B-Finanzierungsrunde in Höhe von 107 Millionen US-Dollar und Erweiterung des Vorstands bekannt
--Mit den Erlösen wird die Pipeline des Unternehmens an Zytokin-Immuntherapien der nächsten Generation vorangetrieben----Laura Shawver, Christine Siu...- Published at
- by globenewswire.com
neutralneutralBright Peak Therapeutics Announces $107 Million Series B Financing and Expanded Board of Directors
--Proceeds to advance company’s pipeline of next-generation cytokine immunotherapies----Laura Shawver, Christine Siu join as independent directors-- ...- Published at
- by gurufocus.com
mixedmixed- Published at
- by markets.businessinsider.com
mixedmixedThe Daily Biotech Pulse: Moderna Coronavirus Vaccine Receives Third Regulatory Nod, Gritstone Rallies On Hedge Fund Stake, aTyr's COVID-19 Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Ja...TPMR.MUTPMR.FTPMR.BETNXPSLNPRLDPRAHPMVPPGENPBYIOTICOCGNNGMMRNA.MXMRNAMASI.MXMASILIFEJAGXIMU.MUIMU.FIMU.DEIMU.BEIMGNIMABI5X.FGRTSGBIOFLGT.MXFLGTFATEF6T.FF6T.BEF2KA.FEO7.MUEO7.FEO7.BEENDPEIDXDMACCRISCMPIC6K.FBX2.MUBX2.FBX2.BEBTAIAIO.MUAIO.FAIO.BEABMD8PH.SG8PH.MU8PH.F8PH.BE7OT.MU7OT.F7F0.F7F0.BE471A.F471A.BE3M4.MU3M4.F3M4.BE2JQ.SG2JQ.MU2JQ.F2H51.F2H51.BE1JA2.SG1JA2.F1JA2.BE0VY.F0QF.SG0QF.MU0QF.F0QF.BE0PB.F0PB.BEZSANXTLBVVOSVTGNTCONT051.FT051.BEICPTI4P.MUI4P.FI4P.BEH2K2.SGH2K2.FH2K2.BECUSA.FCUSA.BECLPTCERCBNGO.MXBNGOBBIOBASIAVIRARVN2Y3.MU2Y3.BE2CL.MU2CL.F0ZPN.SG0ZPN.F0ZPN.BEUTHRUTH.SGUTH.MUUTH.FUTH.BEMYOVMRSNFDMTCALAAPRE71M.SG71M.F71M.BE2CB.F2CB.BE0M4.F0M4.BE- Published at
- by benzinga.com
mixedmixedStocks That Hit 52-Week Highs On Monday
During Monday's morning session, 286 stocks hit new 52-week highs. Areas of Interest: The company with the largest market cap to set a new ...X9C.MUWMSWITWCCWBAIVTGNVRAYVMIUTHRUNITUISTWNKTURNTTCTPRTPCOTLSTERTCONSYKSTKLSSTKSQM-B.SNSQM-A.SNSNSSSNPSSNESMTXSMTSSMTCSMT.TOSMPLSMGSLABSIVBSILCSIFSI7.BESBUXSARYIRXNRSROCKROADRIOTRDWRRDCMRBCPRAHPMVPPKGPKA.SGPKA.MUPKA.FPANDOZKORAONTOONNWLNNM.FNCTYMYRGMYEMXIMMTA.VMTAMRVLMMYTMLRMGLNMASIMAGLSPDLSCCLPROLPLLCTX.TALCTXKSUKLACKEYSKCY.SGKCY.MUKCY.FKCY.BEJYNTJAGXISIGIPHIIPGPINVEIECIDXXIDNICEHPQHIGLEOGLDDGFLGATOFSMFRCFLXSFLGTEYPTEXPEEXPEXKEWBCERIIEQOSEMXEIMEIDXDVADMYT-UNDMYTDJCODFXN.FDDDCBODARDACCURICRVLCRISCREECLPTCLFCHXCEVACDNSCATBTBTBO8.MUBO8.FBO8.BEBNGOBLKBGBCOVBBLBBIOBASIAZREAVYAVNTAVIRAVIDAVGOAUMNATOMASMLARVNAQMSAPTVANTEANSSAMRSAMEALBALACAESADSKADOCADIACORABMD81R.F81R.BE3E0.FSILVSIL.TOSGRYSBSWQUMUPGENOCUPOCGNMXLMTRNMPWRMOSMLMLTHMJEFINTTGSLFCXENDPDMACCRHBSYBRGBKO.SGBKO.FATSGATRALLYAAXYLMU.MIMUFOURBIDUBCPCASX